IRLAB Therapeutics Stock Forward View - Unknown Technical Ratio
| IRLAB-A Stock | SEK 1.48 -0.10 -6.33% |
This reference page presents Revenue forecast data for IRLAB Therapeutics AB. The projected values and error metrics are presented below as reference information.
This Revenue forecast data for IRLAB Therapeutics AB is sourced from the most recent available trading data and is intended solely as reference information. Revenue Analysis Today
IRLAB Therapeutics AB has current Revenue of 0.| Previous Revenue | Revenue | Trend |
| 0 | 0 |
| Volatility | Backtest | Information Ratio |
IRLAB Therapeutics Trading Date Momentum
| On March 23 2026 IRLAB Therapeutics AB was traded for 1.48 at the closing time. The highest price during the trading period was 1.55 and the lowest recorded bid was listed for 1.45 . The volume for the day was. This history from March 23, 2026 did not cause price change. The trading delta at closing time to the current price is 4.73% . |
| Compare IRLAB Therapeutics to competition |
Other Forecasting Options for IRLAB Therapeutics
IRLAB Therapeutics' daily price returns can be decomposed into trend, seasonal, and residual components. Divergence between short-term and long-term averages in IRLAB often signals an upcoming reversal or acceleration.IRLAB Therapeutics Related Equities
Checking IRLAB Therapeutics against related firms within the Biotechnology space helps investors see where the stock stands among peers. Return on equity across these peers shows how well each firm turns capital into profit. Falling behind peers on key ratios may signal headwinds or execution issues worth looking into.
| Risk & Return | Correlation |
IRLAB Therapeutics Market Strength Events
Market strength indicators help investors evaluate how IRLAB Therapeutics stock reacts to evolving market conditions. These indicators help determine optimal entry and exit points for trading IRLAB Therapeutics AB.
IRLAB Therapeutics Risk Indicators
The analysis of IRLAB Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. Understanding the risk involved in holding IRLAB Therapeutics' allows investors to make informed decisions about their exposure.
| Mean Deviation | 2.43 | |||
| Standard Deviation | 3.34 | |||
| Variance | 11.16 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for IRLAB Therapeutics
Story coverage around IRLAB Therapeutics AB often expands when market conditions, narrative momentum, or risk-adjusted performance make the security more visible to investors. A disciplined read of coverage separates durable relevance from temporary noise.
Other Macroaxis Stories
Macroaxis story coverage is designed for a broad investing audience that ranges from self-directed traders to advisers, researchers, and institutional market participants. The content is intended to support people who want a more structured path from headline information to portfolio action.
Story Categories
Currently Trending Categories
IRLAB Therapeutics Short Properties
Reviewing short-oriented indicators for IRLAB Therapeutics AB is useful because long and short participants often create very different signals for timing and volatility. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 401.9 M |
More Resources for IRLAB Stock Analysis
Other Information on Investing in IRLAB Stock
Financial ratios for IRLAB Therapeutics show relationships between important financial metrics. All figures are sourced from the latest available reporting inputs and presented as reference data.